More Data Backs Tecentriq As IMpower133 Combo Meets Primary SCLC Endpoints

 
• By Sten Stovall

IMpower133 trial combining Tecentriq with chemotherapy in first-line small cell lung cancer met both its OS and PFS endpoints.

Carcinoma
Roche has 8 Phase III lung cancer studies underway evaluating Tecentriq alone or in combination • Source: Shutterstock

More from Immuno-oncology

More from Anticancer